Akebia Therapeutics, Inc. (AKBA) Stock Score, Valuation & Financial Research
Akebia Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for AKBA
Akebia Therapeutics, Inc. currently has a Wall Street Score of 21/100. The stored market price is $0.9. Its financial score is 14/100. Its valuation score is 0/100. The latest WSS change is -0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Akebia Therapeutics, Inc. does
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United
AKBA financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $0.9
- Market capitalization:
- $242.2M
- Revenue:
- $219.1M
- Net income:
- $-29.7M
- Free cash flow:
- $67.7M
- Cash:
- $155.5M
- Total debt:
- $54.0M
- EPS:
- -0.11
- Financial score:
- 14/100
- Valuation score:
- 0/100
- Revenue score:
- 16/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $67.7M, showing positive cash generation.
- The balance sheet shows $155.5M of cash versus $54.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.3 points: AKBA decreased 0.3 points because Asset declined by 2.1 points.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 14/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AKBA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.